ArticleCureus2025
A Clinical Picture of Amyopathic Dermatomyositis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinically amyopathic dermatomyositis (CADM) is a rare subset of classic dermatomyositis (DM) with distinct clinical features and unique autoantibody profiles. Affected individuals usually present with the cutaneous signs of DM, without muscle pain, proximal weakness, or abnormal muscle labs and imaging results. Here, we present the case of a 69-year-old Caucasian male for evaluation of a positive antinuclear antibody (ANA) test and an eight-month history of a rash. He had no associated muscle weakness or pain. A physical examination noted a rash characteristic of dermatomyositis, including pathognomonic Gottron's papules. Skin biopsies were inconclusive, and labs were negative for anti-Jo1 antibodies or elevated muscle enzymes. Treatment was first initiated with hydroxychloroquine before ultimately being switched to methotrexate, which was more effective for him.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.